Antitumor effect of Pt(II) amine phosphonate complexes on sarcoma Sa-180 in mice. Crystal structure of cis-dichlorobis(diethyl-4-pyridylmethyl-phosphonate- κN)platinum(II) hydrate, cis-[PtCl2(4-pmpe)2] · H2O

Pharmazie

Volumn 61, Issue 5, 2006, Pages 457-460

  Aranowska, K ^a   Graczyk, J ^a   Checinska L ^b   Pakulska, W ^a   Ochocki, Justyn ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CISPLATIN DERIVATIVE; CREATININE; PLATINUM (2 PYRIDYLMETHYLPHOSPHONATE) 2 CL2; PLATINUM (3 PYRIDYLMETHYLPHOSPHONATE) 2 CL2; PLATINUM (4 PYRIDYLMETHYLPHOSPHONATE) 2 CL2; PLATINUM (II) AMINE PHOSPHONATE COMPLEX; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; GEOMETRY; HYDROGEN BOND; INFRARED SPECTROMETRY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; SARCOMA 180; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; HYDROGEN BONDING; INDICATORS AND REAGENTS; KIDNEY DISEASES; LETHAL DOSE 50; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; ORGANOPLATINUM COMPOUNDS; SARCOMA 180; SPECTROPHOTOMETRY, INFRARED; X-RAY DIFFRACTION;

EID: 33646692689     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23: 460-464.
2. Haines KR, Lippard SJ (2004) Cisplatin and related anticancer drugs: recent advances and insights. Met Ions Biol Syst 42: 143-177.
3. Bloemink MJ, Diederen JJH, Dorenbos JP, Heetebrij RJ, Keppler BK, Reedijk J (1999) Calcium ions do accelerate the DNA binding of new antitumor-active platinum aminophosphonate complexes. Eur J Inorg Chem 9: 1655-1657.
4. Brzezińska-Blaszczyk E, Mińcikiewicz M, Ochocki J (1996) Effect of cisplatin and cis-platinum(II) phosphonate complex on murine mast cells. Eur J Pharmacol 298: 155-158.
5. 2O. Acta Cryst E59: m350-352.
6. Deichmann WB, Le Blanc TJ (1943) Determination of the approximate lethal dose with about six animals. J Industr Hyg Toxicol 25: 415-418.
7. 2]. J Indian Chem 8: 193-194.
8. Goldin A, Veneditti JM, Mantel N (1961) Preclinical screening and evaluation of agents for the chemotherapy of cancer: A review. Cancer Res 21: 1334-1351.
9. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, Kelland LR (1998) Chemical, biological and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2- methylpyridine)] platinum(II) (AMD473). Anti-Cancer Drug Design 13: 1-18.
10. +. J Med Chem 32: 128-136.
11. Hollis LS, Miller AV, Amundsen AR, Schurig JE, Stern EW (1990) cis-Diamineplatinum(II) complexes containing phosphono carboxylate ligands as anticancer agents. J Med Chem 33: 105-111.
12. Iba T, Yagi Y, Kidokoro A, Fukunaga T (1993) Comparison between leucovorin and cisplatin as a modulator of 5-fluorouracil. Gan To Kagaku Ryoho 20: 479-483.
13. Kadłubowski R (1971) Approximate methods in analysis of dose-response curve. In: Abstracta VIIth International Congress of Chemotherapy 1: A-12/28.
14. Kettle SFA (1996) Physical inorganic chemistry. A coordination chemistry approach. Oxford University Press.
15. Kim DK, Kim G, Gam J, Cho YB, Kim HT, Tai JH, Kim KH, Hong WS, Park JG (1994) Synthesis and antitumor activity of a series of [2-substituted-4,5-bis- (aminomethyl)-1,3-dioxolane] platinum(II) complexes. J Med Chem 37: 1471-1485.
16. Kostka B, Ochocki J (1996) A comparison of the effects of cisplatin and cis-platinum(II) phosphonate complex on ADP-induced platelet aggregation in vitro. Pharmazie 51: 990-992.
17. Lippert B (ed.) (1999) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Verlag, Helv Chim Acta, Zurich, and Wiley-VCH, Weinheim, pp. 1-563.
18. Meulenaer de J, Tompa H (1965) The absorption correction in crystal structure analysis. Acta Cryst 19: 1014-1018.
19. Molecular Structure Corporation (1989) MSC/AFC Diffractometer Control Software. MSC, 3200 Research Forest Drive, The Woodlands, TX. 77381, USA.
20. Najman-Bronzewska L, Ochocki J (1997) In vitro alkylating of α,β-unsaturated amidoesters, diethyl pyridylmethylphosphonates and their cis-Pt(II) complexes. Pharmazie 52: 198-202.
21. Ochocki J, Kostka K, Zurowska B, Mrozinski J, Galdecka E, Galdecki Z, Reedijk J (1992) Synthesis, spectroscopy and magnetism of transition-metal complexes with pyridylmethylphosphonate complexes. J Chem Soc Dalton Trans: 2955-2960.
22. Ochocki J, Erxleben A, Lippert B (1997) Synthesis and spectroscopy of phosphonate derivatives of uracil and thymine. X-ray crystal structure of diethyl 6-uracilmethylphosphonate. J Heterocycl Chem 34: 1-6.
23. 2 showing unexpected O-binding of the qmpe ligands. Eur J Inorg Chem: 169-175.
24. O'Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59 Suppl 4: 19-27.
25. Orpen AG, Brammer L, Allen FH, Kennard O, Watson DG, Taylor R (1989) Tables of bond lengths determined by X-ray and neutron diffraction. Part 2. Organometallic compounds and co-ordination complexes of the d- and f-block metals. J Chem Soc Dalton Trans S1-84.
26. Pawelski S (1977) Laboratory diagnostic. PZWL, Warszawa.
27. Rigaku/MSC (2002) Crystal structure. Version 3.10. Rigaku/MSC, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
28. 2-) in aqueous solution. Inorg Chem 43: 1311-1322.
29. Sheldrick GM (1997) SHELXS and SHELXL97. University of Göttingen, Germany.
30. Spek AL (2001) PLATON. University of Utrecht. The Netherlands.